EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cellular Senescence and the SASP in HFpEF: Pathogenic Mechanisms and Therapeutic Targeting

Qiu-Cheng Zhu, Qiong Zheng, Hao Zhang, Yan Tu, Ping Wang, Xiang-Jie Liu

International Journal of Molecular Sciences · 10.06.2026 · 27 (12) · 5278

DOI: 10.3390/ijms27125278 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.06.2026. Verfasst von Qiu-Cheng Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Li-Yuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China. Hauptthemen laut MEDLINE: Senescence-Associated Secretory Phenotype, Heart Failure, Cellular Senescence, Stroke Volume. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Provincial Administration of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure with preserved ejection fraction (HFpEF) represents a complex syndrome strongly associated with aging, characterized by diastolic dysfunction, myocardial stiffness, and chronic low-grade inflammation. Cellular senescence and the ensuing senescence-associated secretory phenotype (SASP) significantly contribute to the pathogenesis and progression of HFpEF. This review examines the biological properties of SASP and its mechanistic roles in driving myocardial fibrosis, microvascular dysfunction, and cardiomyocyte injury. We synthesize evidence from preclinical and clinical studies demonstrating how SASP factors orchestrate HFpEF pathophysiology. The therapeutic potential of targeting SASP pathways is critically evaluated, including senolytic agents that eliminate senescent cells and senomorphic compounds that inhibit SASP factor secretion. Finally, we identify key translational barriers, such as limited tissue specificity in senolytic delivery and inadequate SASP biomarkers for treatment monitoring, while outlining future research directions to advance novel therapeutic development for this increasingly prevalent condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Senescence-Associated Secretory PhenotypeHeart FailureCellular SenescenceStroke VolumeHumansAnimalsSenotherapeutics

Stichwörter der Autor:innen

HFpEFSASPcellular senescencesenolyticssenomorphics

Substanzen

Senotherapeutics

Autor:innen und Institutionen

  • Li-Yuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China.
  • Laboratory of Metabolic Abnormalities and Vascular Aging, Huazhong University of Science and Technology, Wuhan 430077, China.

Förderung

  • Hubei Provincial Administration of Traditional Chinese Medicine

Zitieren

APA

Zhu, Q. C., Zheng, Q., Zhang, H., Tu, Y., Wang, P., & Liu, X. J. (2026). Cellular Senescence and the SASP in HFpEF: Pathogenic Mechanisms and Therapeutic Targeting. International Journal of Molecular Sciences, 27(12), 5278. https://doi.org/10.3390/ijms27125278

Vancouver

Zhu QC, Zheng Q, Zhang H, Tu Y, Wang P, Liu XJ. Cellular Senescence and the SASP in HFpEF: Pathogenic Mechanisms and Therapeutic Targeting. International Journal of Molecular Sciences. 2026;27(12):5278. doi:10.3390/ijms27125278

BibTeX
@article{Zhu2026,
  author = {Zhu, Qiu-Cheng and Zheng, Qiong and Zhang, Hao and Tu, Yan and Wang, Ping and Liu, Xiang-Jie},
  title = {Cellular Senescence and the SASP in HFpEF: Pathogenic Mechanisms and Therapeutic Targeting},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {12},
  pages = {5278},
  doi = {10.3390/ijms27125278}
}
Kostenlos starten →